4DMedical (ASX:4DX) Expands Global Lung Health Programs with New Agreements in Brazil and Australia

Sonal Goyal

08 September 2025 10:29 AM AEST

4DMedical (ASX:4DX) Expands Global Lung Health Programs with New Agreements in Brazil and Australia

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

4DMedical partners with a global pharmaceutical company to launch a lung health screening program in Brazil, covering up to 10,000 scans through August 2026.

Royal Melbourne Hospital becomes the first Australian public hospital to pilot 4DMedical’s full suite of respiratory imaging solutions, running until December 2025.

Spectrum Medical Imaging enters into a multi-year agreement with 4DMedical, extending support for Australia’s National Lung Cancer Screening Program until June 2027.

4DMedical Limited (ASX:4DX), a global provider of advanced respiratory imaging solutions, has entered into agreements with a leading pharmaceutical company, Royal Melbourne Hospital, and Spectrum Medical Imaging. The collaborations aim to expand lung health screening, enhance diagnostic insights, and support the rollout of Australia’s National Lung Cancer Screening Program (NLCSP).

Collaboration in Brazil

Under a new agreement with a leading pharmaceutical company, 4DMedical has launched a Lung Health Screening program in Brazil. The initial rollout is underway at Hospital Madre Teresa in Belo Horizonte and is designed to address lung cancer screening while also detecting incidental findings such as coronary artery calcification (CAC) and chronic obstructive pulmonary disease (COPD). The program will analyse up to 10,000 scans through to August 2026, with plans to expand to eight hospitals in the early phase and extend to national coverage.

Pilot with Royal Melbourne Hospital

Royal Melbourne Hospital (Melbourne Health) has entered into a pilot agreement to deploy 4DMedical’s entire portfolio of imaging and analysis tools. This includes CT LVAS™, XV LVAS™, LDAi, LDAf, Lung Texture Analysis, and low-dose CT nodule detection. The pilot program, which will run until 31 December 2025, is aligned with the objectives of the NLCSP. This agreement marks Royal Melbourne Hospital as the first Australian public hospital and Academic Medical Centre to implement the full 4DMedical suite in clinical practice.

Multi-Year Agreement with Spectrum Medical Imaging

4DMedical has also signed a multi-year contract with Spectrum Medical Imaging in New South Wales. Under the agreement, Spectrum will deploy the company’s portfolio of imaging analysis tools to support lung health initiatives, including the National Lung Cancer Screening Program. Spectrum, already a provider of CT LVAS™, will expand its offering to include low-dose CT nodule detection and additional structural and functional reporting tools such as Lung Map for Smoking Cessation, Lung Texture Analysis, LDAi and LDAf.

The agreement, effective immediately and running until 30 June 2027, is structured to integrate 4DMedical’s Software-as-a-Service (SaaS) platform with Spectrum’s existing imaging infrastructure. Financial terms remain undisclosed. Spectrum emphasised the value of the collaboration in improving diagnostic precision, enabling earlier interventions, and delivering actionable insights to clinicians across Australia.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.